Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

The anti-CD20 mAb rituximab has substantially improved the clinical outcome of patients with a wide range of B-cell malignancies. However, many patients relapse or fail to respond to rituximab, and thus there is intense investigation into the development of novel anti-CD20 mAbs with improved therape...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Alduaij, Waleed, Ivanov, Andrei, Honeychurch, Jamie, Cheadle, Eleanor J., Potluri, Sandeep, Lim, Sean H., Shimada, Kazuyuki, Chan, Claude H. T., Tutt, Alison, Beers, Stephen A., Glennie, Martin J., Cragg, Mark S., Illidge, Tim M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3099571/
https://ncbi.nlm.nih.gov/pubmed/21378274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-07-296913
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados